CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in ...

Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of ...

The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent ...

Novo Nordisk rebounds from 2024 lows as GLP-1 supply issues ease, partnerships expand, and valuation turns attractive. Find ...

CHICAGO -- An investigational, oral small-molecule GLP-1 receptor agonist improved glycated hemoglobin levels in adults with ...

Approximately 15 million Americans are on a GPL-1 or better known as Ozempic, Wegovy and Zepbound but there will be upcoming ...

GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...

Patients on GLP-1 medications lost about half as much weight as participants did in clinical trials, NYU researchers found.

Bariatric surgery is associated with a significantly greater long-term weight loss than treatment with GLP-1 receptor ...

Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.

Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock is a Hold.

By Dennis Thompson HealthDay ReporterTUESDAY, June 24, 2025 (HealthDay News) — A new Chinese-developed GLP-1 weight loss drug could prove a new competitor to blockbuster drugs Ozempic /Wegovy and ...